Adaptive Biotechnologies Corporation
A maker of tools that read the immune system's genetic code. Its FDA-authorized clonoSEQ test hunts for the tiny traces of cancer cells that can linger after treatment for blood cancers like multiple myeloma, helping doctors spot a possible relapse early. The company was founded in 2009 by brothers Harlan and Chad Robins, after Harlan's lab work at a Seattle research center cracked how to sequence T-cell receptors; Chad, a business guy who joked he couldn't tell a T-cell receptor from a T-bone steak, handled the company side.
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| VIKING GLOBAL INVESTORS LP | 13G/APassive | 18.8% | 29.99M | May 15, 2026 |
| HALVORSEN OLE ANDREAS | 13G/APassive | 18.8% | 29.99M | May 15, 2026 |
| Shabet Rose Sharon | 13G/APassive | 18.8% | 29.99M | May 15, 2026 |
| VIKING GLOBAL PERFORMANCE LLC | 13G/APassive | 13.8% | 22.00M | May 15, 2026 |
| Viking Global Equities Master Ltd. | 13G/APassive | 13.5% | 21.56M | May 15, 2026 |
| Viking Long Fund GP LLC | 13G/APassive | 5% | 7.99M | May 15, 2026 |
| Viking Long Fund Master Ltd. | 13G/APassive | 5% | 7.99M | May 15, 2026 |
| Viking Global Equities II LP | 13G/APassive | 0.3% | 440.0K | May 15, 2026 |
| The Vanguard Group | 13G/APassive | 0% | 0 | Mar 26, 2026 |
| BlackRock, Inc. | 13G/APassive | 7.9% | 11.99M | Jan 21, 2026 |